RVAC Medicines Pte. Ltd. (RVAC),&nbsp;a messenger RNA (mRNA) technology platform company, announced today that it has secured the approval from the Health Sciences Authority (HSA) to initiate Phase&nbsp;1B&nbsp;clinical trial in&nbsp;Singapore&nbsp;to evaluate the safety and immunogenicity of three COVID-19 mRNA vaccine candidates.

The clinical trial aims to evaluate three of RVAC's COVID-19 vaccine candidates that include one against the ancestral strain, one against an Omicron strain, and a bivalent vaccine candidate with components of both ancestral and Omicron strains. The study will commence in February 2023&nbsp;in partnership with&nbsp;Singapore's&nbsp;National Centre for Infectious Diseases (NCID).

"The initiation of&nbsp;Singapore&nbsp;clinical studies is an important milestone in the development our COVID-19 vaccine candidates," commented Dr.&nbsp;Sean Fu, Chief Executive Officer of RVAC. "It is also a strong validation of RVAC's mRNA platform which will further accelerate the advancement of future pipeline projects," he added.

Associate Professor&nbsp;Barnaby Young, Head of Singapore Infectious Disease Clinical Research Network, NCID and Principal Investigator for the study, said, "I am delighted that our team at NCID is working with RVAC to develop a bivalent COVID-19 vaccine in&nbsp;Singapore. This vaccine has the potential to enhance protection against SARS-CoV-2 and emerging variants, keeping&nbsp;Singapore&nbsp;safe and resilient against future waves of infection."

This is RVAC's second clinical trial. The first was initiated in&nbsp;September 2022&nbsp;in&nbsp;Australia&nbsp;(clinicaltrials.gov identifier: NCT05420077).

Since its founding in 2021, RVAC has recruited a team of scientists and industry veterans, and established R&amp;D centers in Boston,&nbsp;Singapore, and&nbsp;Shanghai. Beyond the COVID-19 vaccine candidates, RVAC is developing other mRNA-based vaccines and therapeutics, targeting infectious diseases such as respiratory syncytial virus (RSV) and&nbsp;Clostridioides difficile&nbsp;infection (CDI), and other diseases.

RVAC Medicines is an mRNA platform company headquartered in&nbsp;Singapore&nbsp;with R&amp;D centers in&nbsp;Boston&nbsp;and&nbsp;Shanghai. Leveraging its mRNA technology and strategic partnerships, the company is building a pipeline of novel mRNA vaccines and therapeutics to address unmet medical needs, particularly in emerging markets. The company is led by an experienced management team, supported by a world-renowned scientific advisory board. For more information, please visit&nbsp;<a href="http://www.rvacmed.com/" target="_blank" rel="nofollow">www.rvacmed.com</a>.

<h1>RVAC Medicines Secures HSA Approval to Initiate Phase 1B Clinical Trial in Singapore</h1>RVAC Medicines Pte. Ltd. (RVAC),&nbsp;a messenger RNA (mRNA) technology platform company, announced today that it has secured the approval from the Health Sciences Authority (HSA) to initiate Phase&nbsp;1B&nbsp;clinical trial in&nbsp;Singapore&nbsp;to evaluate the safety and immunogenicity of three COVID-19 mRNA vaccine candidates.The clinical trial aims to evaluate three of RVAC's COVID-19 vaccine candidates that include one against the ancestral strain, one against an Omicron strain, and a bivalent vaccine candidate with components of both ancestral and Omicron strains. The study will commence in February 2023&nbsp;in partnership with&nbsp;Singapore's&nbsp;National Centre for Infectious Diseases (NCID)."The initiation of&nbsp;Singapore&nbsp;clinical studies is an important milestone in the development our COVID-19 vaccine candidates," commented Dr.&nbsp;Sean Fu, Chief Executive Officer of RVAC. "It is also a strong validation of RVAC's mRNA platform which will further accelerate the advancement of future pipeline projects," he added.Associate Professor&nbsp;Barnaby Young, Head of Singapore Infectious Disease Clinical Research Network, NCID and Principal Investigator for the study, said, "I am delighted that our team at NCID is working with RVAC to develop a bivalent COVID-19 vaccine in&nbsp;Singapore. This vaccine has the potential to enhance protection against SARS-CoV-2 and emerging variants, keeping&nbsp;Singapore&nbsp;safe and resilient against future waves of infection."This is RVAC's second clinical trial. The first was initiated in&nbsp;September 2022&nbsp;in&nbsp;Australia&nbsp;(clinicaltrials.gov identifier: NCT05420077).Since its founding in 2021, RVAC has recruited a team of scientists and industry veterans, and established R&amp;D centers in Boston,&nbsp;Singapore, and&nbsp;Shanghai. Beyond the COVID-19 vaccine candidates, RVAC is developing other mRNA-based vaccines and therapeutics, targeting infectious diseases such as respiratory syncytial virus (RSV) and&nbsp;Clostridioides difficile&nbsp;infection (CDI), and other diseases.About RVACRVAC Medicines is an mRNA platform company headquartered in&nbsp;Singapore&nbsp;with R&amp;D centers in&nbsp;Boston&nbsp;and&nbsp;Shanghai. Leveraging its mRNA technology and strategic partnerships, the company is building a pipeline of novel mRNA vaccines and therapeutics to address unmet medical needs, particularly in emerging markets. The company is led by an experienced management team, supported by a world-renowned scientific advisory board. For more information, please visit&nbsp;<a href="http://www.rvacmed.com/" target="_blank" rel="nofollow">www.rvacmed.com</a>.

Medical / Hospital

RVAC Medicines Secures HSA Approval to Initiate Phase 1B Clinical Trial in Singapore

HR / Recruitment

Skin care / Cosmetics / Hair products

Internet service

Film / Drama

Magazines / Books / Publications

Marketing / Research

Diet / Health food / Supplement

Childbirth / Childcare

Interior / Furniture / Storage

Mobile device

Servers / Peripherals

Network / Network Equipment

System / Website / Application development

Electronic components / Semiconductors / Electrical equipment

Department stores / Supermarkets / Convenience stores / Stores

Wholeseller

Manga / Anime

Arcade Game

Toys / Playsets / Dolls

Car / Car Supplies

Motorcycles / Motorcycle Supplies

Daily necessities / Household goods

Garden / DIY

Shoes / Bags

Jewelry / Accessories

Kids / Baby / Maternity

Food / Sweets

Soft Drinks / Alcoholic drinks

Restaurant / Fast food / Streetfood

Eating at home / Delivery

Fitness / Healthcare

Pharmaceuticals

Pets / Pet Supplies

Gifts / Flowers

Love / Marriage

Funeral

Hotels / inns

Travel / Sightseeing

Theme Park / Amusement park

Residential / Condominium

Commercial facilities / Office buildings

Architecture / Space design

Construction / Civil engineering

Advertising / Promotion / PR

Sales

Management Consulting

Think tank

Legal / Patent / Intellectual Property

Logistics / Warehouse / Cargo

Steel / Metal / Glass / Earth / Stone / Rubber

Chemistry

Electricity / Gas / Resources / Energy

Nature / Weather

School / University

Cram school / Preparatory school / Online education

Life insurance / Non-life insurance

Mobile app

Mobile games

Cooking / Home appliances

Health and Beauty appliances

Application

Ladies' Fashion

Men's Fashion

Accounting

Environment / SGDs / Recycling

International activity

Full time job / Part-time job / Career

E-commerce

Music

Internet Service Provider / Line connection

Camera

AV equipment

Consumer Games

Outdoors / Mountain Climbing

Welfare / Nursing / Rehabilitation

Qualifications / Study Abroad / Language

Childcare / Early childhood education

Banks / Credit unions

Credit card / Loan

Securities / FX / Investment Trusts

Moving

Politics / Government / Local government

Volunteer

Agriculture / Forestry / Fisheries

Bicycle / Bicycle Supplies

Female Related

Venture Capitals

Coaching / Mentoring / Consultation

Automotive / Motorcycle / Bicycle

Automotive / Automotive Supplies

Interior / Goods

Real Estate / Architecture / Construction

Software

Blockchain / Web3

Security

Telecommunications / VoIP

Show Business

Comedy

Health